RxDoctor Payments Data

Douglas Johnson, MD

Dermatology · Honolulu, HINPI 1700869427

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $427,186 of the $568,479 with a category attached, or 75.1%. It is spread thinly across 28 manufacturers, the largest accounting for just 15.3%. Reporting peaked in 2024 at $158,532 and has fallen 60.5% since, to $62,605 in 2025. Among dermatology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$568,479in general payments, 2019–2025

Across 1,379 payments — averaging $412.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$87K
  • Lilly USA, LLC$80K
  • UCB, Inc.$74K
  • Regeneron Healthcare Solutions, Inc.$66K
  • Novartis$47K
  • Pfizer$43K
  • plus $172K from 22 others
$135,728in research payments, 2019–2025

Across 2 payments — averaging $67,864 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$136K

What the payments were for

  • Consulting fees$46,3288%
  • Speaking & faculty fees$427,18675%
  • Grants$8,0001%
  • Travel & lodging$50,4819%
  • Food & beverage$36,1486%
  • Education$3360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$568,479 in reported general payments places this provider in the 95th percentile of 67 dermatology providers in Hawaii.

See all dermatology providers in Hawaii

Medicare billing

Part B allowed, 2024
$63,430
Medicare patients
221
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bimzelx AutoinjectorBimekizumab-Bkzx12$166,293
Dupixent SyringeDupilumab41$164,510
Cosentyx Sensoready (2 Pens)Secukinumab11$94,255
Tacrolimus29$5,596
Betamethasone Dipropionate100$4,993
Fluocinonide85$4,024
Clobetasol Propionate33$2,142
Alclometasone Dipropionate45$2,008
Ketoconazole100$1,780
MethotrexateMethotrexate Sodium53$1,632
Triamcinolone Acetonide136$1,475
Hydrocortisone104$1,282
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc26$1,229
Halobetasol Propionate21$1,079
Fluorouracil15$1,069

Paid to pharmacies, not to this prescriber.

Other dermatology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →